

Ignite Proteomics

Patient Focused Precision Medicine in Breast Cancer Treatment using Proteomic Biomarkers

The Ignite Proteomics Breast Assay Offers:

- A quantitative assay providing measurements of abundance and activation of 32 proteins and phosphoproteins in breast cancer pathway - **the drug targets themselves**
- Ability to better define the HER2-low category, currently being missed by standard IHC methods
- A novel Reverse Phase Protein Array (RPPA) technology and Laser Capture Microdissection (LCM) requiring a very small sample size
- Comprehensive Results with >90% Actionability and >75% Clinical Utility
- Commercial Access to patients with advanced stage breast cancer

“The RPPA assay allows me to understand which protein biomarkers and signaling pathways are active and driving my patient’s metastatic breast cancer growth. Proteomic information can be instrumental in helping guide therapy choices for my patients.” **Joyce O’Shaughnessy, MD**

The Ignite Proteomics Breast Assay measures both abundance AND activation of these key proteins...

PI3K/AKT/mTOR Signaling	EGFR/HER2 Signaling	Oncogenic RTK Signaling	Stem Cell Signaling
AKT _{1/2/3} ^{T308}	HER2 ^{Total}	FGFR ^{Y653/Y654}	TROP2 ^{Total}
AKT _{1/2/3} ^{S473}	HER2 ^{Y1248}	PDGFRB ^{Y751}	JAK2 ^{Y1007/Y1008}
mTORC1 ^{S2448}	HER3 ^{Y1289}	RET ^{Y905}	STAT3 ^{Y705}
4E-BP1 ^{S65}	EGFR ^{Y1068}	MET ^{Y1234/Y1235}	Tumor Microenvironment
p70S6K ^{T389}	EGFR ^{T654}	ALK ^{Y1604}	VEGFR2 ^{Y951}
rpS6 ^{S235/S236}	RAS/MEK/ERK Signaling	Shc ^{Y317}	SRC ^{Y416}
	MEK _{1/2} ^{S217/S221}	Androgen Signaling	Paxillin ^{Y118}
Cell Cycle Regulation	ERK _{1/2} ^{T202/Y204}	AR ^{Total}	Immune Checkpoints
FOXM1 ^{T600}	Cellular Proliferation	DNA Damage Response	PD-L1 ^{Total}
Rb ^{S780}	Ki-67 ^{Total}	H2AX ^{S139}	MHCII ^{Total}

...and provides both on-label and off-label recommendations based on these findings

The ordering process:

- 1 Page Test Request Form and pathology report
- Once TRF is received, a kit is shipped to pathology lab based on TRF
- ~14 Day turn around time once sample is received
- Clear, upfront billing policy for providers and patients



For additional information about Ignite Proteomics and our test offering, please contact:

Mike Vallone, Senior Director of Commercialization
mike.vallone@igniteproteomics.com / 201-873-0358

